The DOI matches its Crossref record; 198 of the 198 references it cites were found in a registry or an index.
Tipping the Scales: Peptide-Dependent Dysregulation of Neural Circuit Dynamics in Alzheimer’s Disease
Open accessAbstract
Identifying effective treatments for Alzheimer's disease (AD) has proven challenging and has instigated a shift in AD research focus toward the earliest disease-initiating cellular mechanisms. A key insight has been an increase in soluble Aβ oligomers in early AD that is causally linked to neuronal and circuit hyperexcitability. However, other accumulating AD-related peptides and proteins, including those derived from the same amyloid precursor protein, such as Aη or sAPPα, and autonomously, such as tau, exhibit surprising opposing effects on circuit dynamics. We propose that the effects of these on neuronal circuits have profound implications for our understanding of disease complexity and heterogeneity and for the development of personalized diagnostic and therapeutic strategies in AD. Here, we highlight important peptide-specific mechanisms of dynamic pathological disequilibrium of cellular and circuit activity in AD and discuss approaches in which these may be further understood, and theoretically and experimentally leveraged, to elucidate AD pathophysiology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Together with our data showing an increased number of Aβ-producing oligodendrocytes in deeper cortical layers of the brains of individuals with AD, these results indicate that oligodendrocyte-derived Aβ plays a pivotal role in the early impairment of neuronal circuits in AD [52]”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [52]
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Alzheimer Disease Genetics Consortium (ADGC), Kunkle, B. W., The European Alzheimer’s Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, P. A. E. R. F. A. D. C. (., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0358-2 · Cited by 2,946
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
The Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
Flagged first, then by citations
Cited by
Sorted by citations
Maestú, F., de Haan, W., Busche, M. A., & DeFelipe, J. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101372 · Cited by 245
Self-citationMeftah, S., & Gan, J. (2023) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2023.1129036 · Cited by 205
Targeting neuroinflammation in Alzheimer’s disease: from mechanisms to clinical applications
Si, Z.-Z., Zou, C.-J., Mei, X., Mei, X., Luo, H., Shen, Y., Hu, J., Li, X.-X., Wu, L., & Liu, Y. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.353484 · Cited by 199
Vogel, J. W., Corriveau‐Lecavalier, N., Franzmeier, N., Pereira, J. B., Brown, J. A., Maaß, A., Botha, H., Seeley, W. W., Bassett, D. S., Jones, D. T., et al. (2023) · Nature reviews. Neuroscience · doi:10.1038/s41583-023-00731-8 · Cited by 180
Amyloid-β: a potential link between epilepsy and cognitive decline
Romoli, M., Sen, A., Parnetti, L., Calabresi, P., & Costa, C. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00505-9 · Cited by 133
Metadata
- Authors
- Harris, S. S., Wolf, F., De Strooper, B., & Busche, M. A.
- Affiliations
- Bernstein Center for Computational Neuroscience Göttingen (DE)
- UK Dementia Research Institute (GB)
- Corresponding author
- Busche, Marc Aurel
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 107
- Issue
- 3
- Pages
- 417-435
- ISSN
- 0896-6273 (ISSN-L)
- OpenAlex
- W3037412948
- Cited by
- 161
- References
- 198
- Citations by year
- 2026: 15 · 2025: 25 · 2024: 35 · 2023: 26 · 2022: 27 · 2021: 28 · 2020: 5
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Neuron (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (submittedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, other-oa)
- Funders
- Bernstein Center for Computational Neuroscience Tübingen (01GQ1005B)
- Medical Research Council (MR/S017003/1)
- Deutsche Forschungsgemeinschaft (CRC889, CRC1286)
- UK Research and Innovation
- VWR Foundation
- UK Dementia Research Institute
- Max-Planck-Gesellschaft
- Alzheimer’s Research UK
- Alzheimer's Society
- Global Innovation Fund
- German-Israeli Foundation for Scientific Research and Development (906-17.1/2006)
- BrightFocus Foundation (A2019112S)
- Volkswagen Foundation (ZN2632)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, neural circuit dynamics, amyloid-beta oligomers, amyloid precursor protein, neuropeptides, soluble APP alpha, tau protein, neuronal hyperexcitability, disease heterogeneity, personalized treatment
- MeSH terms
- Axon Initial Segment, Alzheimer Disease, Animals, Astrocytes, Brain, Humans, Neural Pathways, Neurons, Peptide Fragments, Seizures, Synapses, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, tau Proteins, Receptors, Glutamate, Microglia, Amyloid Precursor Protein Secretases, NAV1.1 Voltage-Gated Sodium Channel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
